Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Happy Birthday may it be filled with joy and rebirth for humanity.
Link to Michael J Fox webinar at 12 EDT
The Michael J. Fox Foundation's webinar "Looking Deep into Cells for the Answers to Parkinson's" begins in two hours.
LIVE WEBINAR DATE: May 16, 2019
LIVE WEBINAR TIME: 12:00 PM EDT
Use the link below to enter the webcast up to 15 minutes before the start.
WEBINAR LINK: https://event.on24.com/wcc/r/1991304/674B7B6FEBBEA62BAD194DE6B58BA762?
The webinar will be available to watch on-demand at the same link after the live webcast. Watch our full library of past webinars at www.michaeljfox.org/webinars.
Thank you and enjoy the webinar!
I posed a question in regards to Sigma 1 receptors, might they slip up and
give us insight into what's happening? Could this be the moment when the dam breaks?
Michael J Fox Third Thursday Webinar Link
https://www.michaeljfox.org/understanding-parkinsons/webinar-registration.php?id=57&e=1991304&k=5195B5442F0C32007FC6E653005AFEB5&em_cid=mc-a1b1R0000086dS5&et_cid=1275947&et_rid=267577387&et_lid=Beyond+Medication%3a+Deep+Brain+Stimulation+and+Focused+Ultrasound+for+Parkinson%26amp%3b%23x27%3bs&em_cid=
Looking Deep into Cells for the
Answers to Parkinson's
Thursday, May 16, 2019, 12 to 1 p.m. ET
Don't know if anyone has posted this, but it looks interesting...
FINRA shows no short interest
Yet NASDAQ shows a slow cover with 5 million short. Hmmm, who to believe.
I think there's a large short position, on the other hand, if the shorts
have managed to cover... this would be a huge sign that the price is about
to increase significantly.
IMHO
link to the annual report online
http://www.viewproxy.com/anavex/2019/10KReport2018.pdf
Rare disease codes
This has made me wonder, how many diseases are there? I did a quick google
and estimated 25k-28k. Has anyone else tried to come up with a number?
And as an extension, how many could our drug have a positive effect?
-TIA
Interesting read on Epilepsy
New article in Nature on transmission of Alzheimer
https://www.nature.com/articles/d41586-018-07735-w
Here here Aero
Jon you make a good point by showing why we shouldn't rush to register our trial as a phase 3. More eyes looking at what we are doing and adding potiential roadblocks. Lay the groundwork that is undeniable so when we are ready the opponents don't have an argument.
Thanks the graph makes it look like 4k 8k 6k trades going off but I couldn't find anything thank you
Hi Xena I was wondering if you saw a volume spike after hours? I looks like there was one on the graph but nothing on NASDAQ was reported. Could you look on your system thx
So they have chosen to box in the 14mg minimum effective dose, thoughts?
Maybe less is needed because of the pathology of Parkinson's? Maybe has
to do with dystonia?
TIA
Thank you, agreed lower dose is interesting.
Posted by Andy Bio on Twitter
Treatment did worse in phase 2 vs placebo looks like they gleaned information from a sub group to come up with this result.
$GRFS long-awaited AMBAR data at #CTAD2018 (link: https://www.prnewswire.com/news-releases/grifols-demonstrates-a-significant-reduction-61-in-the-progression-of-moderate-alzheimers-disease-using-its-ambar-treatment-protocol-300738956.html) prnewswire.com/news-releases/… Claims to hit in moderate but not mild pts - ADAS-Cog p=0.05 shouldn't be stat sig w/ multiplicity adj. - ADCS-ADL p=0.002 but in previous Ph2 actually did worse than pbo - Need full baseline characteristics etc
Oops right. That makes sense.
Participant duration could it be read as 12 months of being in the trial? Though the trial lasts 48 months.
FDA has issues
Thank you for putting up the CC, that was enlightening, frustrating, and
maddening all at the same time. Thank God we have the ability to work
around the FDA roadblock and move forward.
That was a big nothing, just more Biogen pumping.
Xena I think you are on point the pump before the dump, miles behind Anavex, just a rehash of a phase 2 study.
Thank you for the link. Looking over the presentation it shows a lack of sophistication on how quickly their drug candidates would proceed.
As We approach up coming trials, I believe the new management is more realistic in their timeline estimations having been burned once already. I remain steadfast in the science and ultimate large size of market that 2-73 will control.
The presentation also gave estimated revenue numbers for all of the drugs in the pipeline; looks like they didn't do a good job determining how much money 2-73 has potiential to create. They probably didn't have a good idea of the scope due to research that was being or yet to be conducted.
So yes the company has over promised before, luckily we have new management that appears to have a much better grasp on what is needed to bring our drug to the finishline.
I think they also have a much better idea of potiential revenue, using estimates from UBS and Biogen on how large the CNS revenue will become.
Got a link for that or did you just make it up?
Wow bummer thanks for the update. Just talking to one of their rep.s this morning on the liquid formula side.